GlassScriptPhysician profile
Rishi D Anand
NPI 1457599300
$41,468.56
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $4,255 · 2021: $8,758 · 2022: $263 · 2023: $39.00 · 2024: $22.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $61.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $61.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $35,387.43 | 2019-2022 | |
| Portola Pharmaceuticals, LLC | $4,410.10 | 2019 | |
| Novo Nordisk INC | $441.92 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $224.53 | 2019-2022 | |
| Companion Medical, INC. | $109.35 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $105.84 | 2020-2021 | |
| Abbott Laboratories | $88.42 | 2020-2024 | Aveir |
| Sanofi-Aventis U.S. LLC | $80.00 | 2019 | |
| Shire North American Group INC | $79.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.53 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.23 | 2020-2021 | |
| Amgen INC. | $55.34 | 2019-2022 | |
| Vivus LLC | $49.23 | 2019-2020 | |
| Aytu Biopharma, INC. | $44.50 | 2019 | |
| Insulet Corporation | $41.93 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $37.68 | 2021-2022 | |
| Eisai INC. | $29.85 | 2019 | |
| Lifescan, INC. | $26.58 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $22.53 | 2021 | |
| Valeritas, INC. | $19.89 | 2019 | |
| Abbvie INC. | $15.57 | 2019 | |
| Ascensia Diabetes Care US INC. | $15.41 | 2021 | |
| Zealand Pharma US, INC. | $14.82 | 2021 | |
| Becton, Dickinson and Company | $13.96 | 2019 | |
| Corcept Therapeutics | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rishi Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.